ISELIN, N.J., Oct. 27, 2016 /PRNewswire/ -- Aimed at capturing the latest developments and breakthroughs against antimicrobial
In the run-up to the event, SMi Group have released an attendee list featuring a global audience that emphasises a widespread international concern on the serious global threat of antibiotic resistance.
Nations present will include Belgium, France, India, Russia, Spain, Sweden, Switzerland, United Kingdom and USA.
A snapshot of organisations confirmed to join Superbugs & Superdrugs USA include:
ABAC Therapeutics, Achaogen, Allecra Therapeutics, AstraZeneca, BARDA, Blueberry Therapeutics Ltd, Bugworks Research India, CUBRC, Destiny Pharma Ltd, Entasis Therapeutics, Janssen Research & Development, LLC, JSC R-PHARM, Merck, Mail Stop K-15-F 370, Micromyx LLC, Modern Medical PC, Morton Findlay Associates Ltd, Motif BioSciences, National Institute Of Allergy & Infectious Diseases, NeoSome Life Sciences LLC, Noigel LLC, Pan American Health Organization (PAHO), Pfizer Antibacterials RU, PHARMA OMNIUM, Phico Therapeutics Ltd, Polyphor Ltd, Purdue Pharma, Sanderling Consulting LLC, Seventure Partners, Spero Therapeutics, The Medicines Company, University of North Texas Health Science Center, Venaticus AB, Zoetis + more.
When asked what was being done to strengthen the antibiotic pipeline, Dr. Christopher Houchens, Branch Chief of BARDA's Antibacterials Program and one of this year's keynote speakers said:
"BARDA and NIAID have worked together to support the establishment of a Biopharmaceutical Accelerator. The CARB-X, represents one of the world's largest public-private partnerships focused on the preclinical discovery and development of new antimicrobial products. This partnership between BARDA, NIAID, the Wellcome Trust of London, the AMR Centre of Alderley Park, and Boston University School of Law, promotes innovation and funding to accelerate the number of antibacterial candidates in the preclinical drug-development pipeline. The end goal of CARB-X is to move promising antibiotic candidates through preclinical development to the point where they would merit additional private and/or public investment for clinical development and regulatory approval."
A preliminary list of attendees and a series of interviews with some of those speaking such as Pfizer, Janssen and BARDA, is available to read in the event download centre.
Further information including a detailed program and full speaker line-up is available at www.superbugs-usa.com.
Superbugs & Superdrugs USA 2016Conference: Nov 14 – 15Interactive workshops: Nov 16Renaissance Woodbridge Hotel, Iselin, New Jersey
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: firstname.lastname@example.orgTo register for the conference, visit http://www.superbugs-usa.com/prlogFor delegate enquires contact Matthew Apps on Tel: +44 (0)20 7827 6093 / Email: email@example.comFor sponsorship or exhibitor enquiries, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: firstname.lastname@example.org
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Press release distributed by PRLog
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/superbugs-attendee-list-released-featuring-leading-health-experts-from-us-government-bodies-industry-and-science-300353165.html
SOURCE SMi Group
Subscribe to our Free Newsletters!